Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)

Inclusion Criteria: * Signed and dated informed consent from patient and/or legally acceptable representative has been obtained * Outpatients of any sex or ethnic origin * Patients \>= 2 years of age (depending on study step) * Patients must be suffering from primary bullous/non-bullous impetigo or SITL Exclusion Criteria: * Presence of skin diseases at or near the investigational area * Immunosuppressed state or other serious systemic disease * Signs and/or symptoms of systemic infection * Presence of skin infection/disorder not amenable to topical antibacterial treatment only * Presence of secondarily-infected animal/human bite * Presence of secondarily infected burnwound * Topical or systemic use of medicinal or other products before or during the study which in the investigators opinion could confound the evaluation of the effect of the study drugs * Known or suspected hypersensitivity to TD1414 or any of the excipients in the TD1414 2% cream * Known or suspected hypersensitivity to mupirocin or any of the excipients in the Bactroban® (mupirocin) 2% cream * Participation in any other investigational drug study or use of (an) investigational drug(s) within the 30 days or 5 half-lives (whichever is longer) prior to randomisation * Patients previously enrolled/randomised in this study * Abnormal ECG at baseline though the PR interval may be up to 220 ms, the QRS interval up to 110 ms and the QTc interval up to 450 ms